Author:
McEvoy Joseph,Gandhi Sanjay K.,Rizio Avery A.,Maher Stephen,Kosinski Mark,Bjorner Jakob Bue,Carroll Benjamin
Funder
Teva Pharmaceutical Industries
Publisher
Springer Science and Business Media LLC
Subject
Public Health, Environmental and Occupational Health
Reference25 articles.
1. Cornett, E. M., Novitch, M., Kaye, A. D., Kata, V., & Kaye, A. M. (2017). Medication-induced tardive dyskinesia: A review and update. Ochsner Journal,17(2), 162–174.
2. Aquino, C. C., & Lang, A. E. (2014). Tardive dyskinesia syndromes: Current concepts. Parkinsonism and Related Disorders,20(Suppl 1), S113–S117.
https://doi.org/10.1016/S1353-8020(13)70028-2
.
3. Zutshi, D., Cloud, L. J., & Factor, S. A. (2014). Tardive syndromes are rarely reversible after discontinuing dopamine receptor blocking agents: Experience from a university-based movement disorder clinic. Tremor and Other Hyperkinetic Movements (N.Y.),4, 266.
https://doi.org/10.7916/d8ms3r8c
.
4. Coplan, J., Gugger, J. J., & Tasleem, H. (2013). Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. Journal of Affective Disorders,150(3), 868–871.
https://doi.org/10.1016/j.jad.2013.04.053
.
5. Waln, O., & Jankovic, J. (2013). An update on tardive dyskinesia: From phenomenology to treatment. Tremor and Other Hyperkinetic Movements (N.Y.).
https://doi.org/10.7916/d88p5z71
.
Cited by
35 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献